Masvik Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 02-07-2024
- Paid Up Capital ₹ 0.10 M
as on 02-07-2024
- Company Age 7 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 52.48%
(FY 2020)
- Profit 31.33%
(FY 2020)
- Ebitda 12.56%
(FY 2020)
- Net Worth 12.94%
(FY 2020)
- Total Assets 25.38%
(FY 2020)
About Masvik Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Jitendra Singh and Vinita Singh serve as directors at the Company.
- CIN/LLPIN
U24303MH2017PTC292915
- Company No.
292915
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Mar 2017
- Date of AGM
31 Dec 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Masvik Pharmaceuticals Private Limited offer?
Masvik Pharmaceuticals Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Protein Powder, Mineral Supplement, Common Disease Medicines, Antiseptic Mouthwashes.
Who are the key members and board of directors at Masvik Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vinita Singh  | Director | 23-Mar-2017 | Current |
| Jitendra Singh | Additional Director | 04-Apr-2018 | Current |
Financial Performance of Masvik Pharmaceuticals.
Masvik Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 52.48% increase. The company also saw a substantial improvement in profitability, with a 31.33% increase in profit. The company's net worth Soared by an impressive increase of 12.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Masvik Pharmaceuticals?
In 2020, Masvik Pharmaceuticals had a promoter holding of 50.00% and a public holding of 50.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Groove Pharmaceuticals Private LimitedActive 7 years 9 monthsJitendra Singh and Vinita Singh are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Masvik Pharmaceuticals?
Unlock and access historical data on people associated with Masvik Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Masvik Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Masvik Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
